Comparative Pharmacology
Head-to-head clinical analysis: AFIRMELLE versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFIRMELLE versus NYLIA 7 7 7.
AFIRMELLE vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive